9 Result(s)
-
Article
Open AccessAutomating Rey Complex Figure Test scoring using a deep learning-based approach: a potential large-scale screening tool for cognitive decline
The Rey Complex Figure Test (RCFT) has been widely used to evaluate the neurocognitive functions in various clinical groups with a broad range of ages. However, despite its usefulness, the scoring method is as...
-
Article
Open AccessPlasma amyloid-beta oligomer is related to subjective cognitive decline and brain amyloid status
Subjective cognitive decline (SCD) is a target for Alzheimer’s disease prediction. Plasma amyloid-beta oligomer (AβO), the pathogenic form of Aβ in blood, has recently been proposed as a novel blood-based biom...
-
Article
Open AccessAssociations between proton pump inhibitors and Alzheimer’s disease: a nested case–control study using a Korean nationwide health screening cohort
Safety concerns against the use of proton pump inhibitors (PPIs) based on the risk of dementia, especially Alzheimer’s disease (AD), remain controversial. Here, we investigated the likelihood of AD depending o...
-
Article
Open AccessVisuospatial memory impairment as a potential neurocognitive marker to predict tau pathology in Alzheimer’s continuum
Given that tau accumulation, not amyloid-β (Aβ) burden, is more closely connected with cognitive impairment in Alzheimer’s disease (AD), a detailed understanding of the tau-related characteristics of cognitive...
-
Article
Open AccessIdentifying novel genetic variants for brain amyloid deposition: a genome-wide association study in the Korean population
Genome-wide association studies (GWAS) have identified a number of genetic variants for Alzheimer’s disease (AD). However, most GWAS were conducted in individuals of European ancestry, and non-European populat...
-
Article
Open AccessSafety and tolerability of donepezil 23 mg with or without intermediate dose titration in patients with Alzheimer’s disease taking donepezil 10 mg: a multicenter, randomized, open-label, parallel-design, three-arm, prospective trial
High-dose donepezil is currently prescribed for patients with Alzheimer’s disease (AD) who showed poor or waning response to a lower dose at the risk of increasing cholinergic side effects. However, the advers...
-
Article
Open AccessOligomeric forms of amyloid-β protein in plasma as a potential blood-based biomarker for Alzheimer’s disease
Soluble amyloid-β (Aβ) oligomers are the major toxic substances associated with the pathology of Alzheimer’s disease (AD). The ability to measure Aβ oligomer levels in the blood would provide simple and minima...
-
Article
Open AccessChemically treated plasma Aβ is a potential blood-based biomarker for screening cerebral amyloid deposition
Plasma β-amyloid (Aβ) is a potential candidate for an Alzheimer’s disease (AD) biomarker because blood is an easily accessible bio-fluid, which can be collected routinely, and Aβ is one of the major hallmarks ...
-
Article
Open AccessIncreased CSF tau level is correlated with decreased lamina cribrosa thickness
This study was to investigate whether the previously proposed link between Alzheimer’s disease (AD) and decreased retinal nerve fiber layer thickness could be explained by the relationship between abnormal CSF...
